Sun Pharma gets USFDA nod for generic duodenal ulcer capsules

Written by Press Trust of India | New Delhi | Updated: Sep 15 2013, 08:24am hrs
Drug firm Sun Pharmaceutical Industries on Saturday said it has received final approval from the US health regulator for its generic Lansoprazole delayed-release capsules used for treating duodenal ulcer. The US Food and Drug Administration (USFDA) has granted its subsidiary final approval for its abbreviated new drug applications for generic version of Prevacid, Lansoprazole Delayed-Release Capsules USP 15 mg and 30 mg, Sun Pharma said in a statement. The capsules have annual sales of about $430 million in the US, Sun Pharma said.